These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 19648086)

  • 1. Effects of S-hexyl-L-cysteine derivatives on prothrombin activation and clotting time determined in the presence of heparin.
    Midura-Nowaczek K; Bruzgo I; Krajewska D
    Adv Med Sci; 2009; 54(1):47-50. PubMed ID: 19648086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of dipeptide derivatives of S-substituted cysteines on the time of fibrinolysis.
    Midura-Nowaczek K; Bruzgo I; Roszkowska-Jakimiec W; Worowski K
    Rocz Akad Med Bialymst; 1996; 41(2):412-6. PubMed ID: 9020554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heparin and low molecular weight heparins inhibit prothrombinase formation but not its activity in plasma.
    Ofosu FA; Lormeau JC; Craven S; Dewar L; Anvari N
    Thromb Haemost; 1994 Dec; 72(6):862-8. PubMed ID: 7740455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effects of aprotinin on heparinized whole blood activated clotting time and whole blood prothrombin time].
    Wen Z; Zhu F; He X; Xiong S; He S
    Hunan Yi Ke Da Xue Xue Bao; 1997; 22(4):304-6. PubMed ID: 9868081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes.
    Flather MD; Weitz JI; Yusuf S; Pogue J; Sussex B; Campeau J; Gill J; Schuld R; Joyner CD; Morris AL; Lai C; Théroux P; Marquis JF; Chan YK; Venkatesh G; Jessel A
    Eur Heart J; 2000 Sep; 21(17):1473-81. PubMed ID: 10952840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coagulation protein function: the influence of acetaldehyde-modified heparin on thrombin activity.
    Brecher AS; Fu Q
    J Investig Med; 1999 Jan; 47(1):76-80. PubMed ID: 10071484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of a low molecular weight heparin (Fragmin) and of unfractionated heparin on coagulation activation at the site of plug formation in vivo.
    Eichinger S; Wolz M; Nieszpaur-Los M; Schneider B; Lechner K; Eichler HG; Kyrle PA
    Thromb Haemost; 1994 Dec; 72(6):831-5. PubMed ID: 7740450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of enoxaparin and unfractionated heparin on thrombin generation in acute coronary syndromes without ST-segment elevation.
    Salvioni A; Casilli F; Assanelli E; Grazi M; Marenzi G; Guazzi MD
    Thromb Haemost; 2001 Oct; 86(4):991-4. PubMed ID: 11686357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased concentrations of heparinoids are required to inhibit thrombin generation in plasma from newborns and children compared to plasma from adults due to reduced thrombin potential.
    Chan AK; Berry LR; Monagle PT; Andrew M
    Thromb Haemost; 2002 Apr; 87(4):606-13. PubMed ID: 12008942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical evaluation of a new one-stage clotting assay for heparin and low molecular weight heparins.
    Harenberg J
    J Mal Vasc; 1987; 12 Suppl B():68-70. PubMed ID: 2834495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring activated clotting time for combined heparin and aprotinin application: in vivo evaluation of a new aprotinin-insensitive test using Sonoclot.
    Ganter MT; Monn A; Tavakoli R; Genoni M; Klaghofer R; Furrer L; Honegger H; Hofer CK
    Eur J Cardiothorac Surg; 2006 Aug; 30(2):278-84. PubMed ID: 16828293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Usefulness of fibrinopeptide A generation tests in experimental and clinical studies with low molecular weight heparin fractions.
    Emanuele RM; Fareed J; Walenga JM; Hoppensteadt DA; Baker WH
    Semin Thromb Hemost; 1985 Apr; 11(2):121-8. PubMed ID: 4035363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preparation and anticoagulation activity of sodium cellulose sulfate.
    Wang ZM; Li L; Zheng BS; Normakhamatov N; Guo SY
    Int J Biol Macromol; 2007 Oct; 41(4):376-82. PubMed ID: 17602735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perioperative monitoring of primary and secondary hemostasis in coronary artery bypass grafting.
    Hertfelder HJ; Bös M; Weber D; Winkler K; Hanfland P; Preusse CJ
    Semin Thromb Hemost; 2005; 31(4):426-40. PubMed ID: 16149021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of heparin, haemodilution and aprotinin on kaolin-based activated clotting time: in vitro comparison of two different point of care devices.
    Dalbert S; Ganter MT; Furrer L; Klaghofer R; Zollinger A; Hofer CK
    Acta Anaesthesiol Scand; 2006 Apr; 50(4):461-8. PubMed ID: 16548858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticoagulant property of a semi-synthesized sodium beta-1,4-glucan sulfate.
    Wang ZM; Li L; Li B; Guo SY
    Yao Xue Xue Bao; 2006 Apr; 41(4):323-7. PubMed ID: 16856476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the effects of low-molecular-weight and unfractioned heparin in horses.
    Monreal L; Villatoro AJ; Monreal M; Espada Y; Anglés AM; Ruiz-Gopegui R
    Am J Vet Res; 1995 Oct; 56(10):1281-5. PubMed ID: 8928943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced inhibition of activated prothrombin by heparin and venous thromboembolism: heparin resistance revisited.
    Legnani C; Preda L; Palareti G; Lunghi B; Rossi E; Coccheri S
    Haematologica; 2002 Feb; 87(2):182-8. PubMed ID: 11836169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of heparin and hirudin on thrombin generation and platelet aggregation after intrinsic activation of platelet rich plasma.
    Gallistl S; Muntean W; Leis HJ
    Thromb Haemost; 1995 Oct; 74(4):1163-8. PubMed ID: 8560429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of melagatran on prothrombin time assays depends on the sensitivity of the thromboplastin and the final dilution of the plasma sample.
    Mattsson C; Menschiek-Lundin A; Wåhlander K; Lindahl TL
    Thromb Haemost; 2001 Aug; 86(2):611-5. PubMed ID: 11522011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.